Carolina Business Review: Panel Interview with BioAgilytix CEO Jim Datin

BioAgilytix in the News

Bioanalysis Zone logo
8 May, 2015

Evaluating the Immunogenicity of Antibody–drug Conjugates

Antibody–drug conjugates (ADCs) represent an innovative therapeutic approach that provides novel treatment options and hope for patients with cancer and infectious disease. In fact, ADCs are quickly becoming one of the fastest growing classes of oncology therapeutics in the pipelines of many pharmaceutical companies.

Read More